Latest Insider Transactions at Neogenomics Inc (NEO)
This section provides a real-time view of insider transactions for Neogenomics Inc (NEO). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of NEOGENOMICS INC to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of NEOGENOMICS INC's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 01
2021
|
Douglas M Van Oort Director |
SELL
Payment of exercise price or tax liability
|
Direct |
5,919
-0.24%
|
$272,274
$46.1 P/Share
|
|
Jul 05
2021
|
Jennifer Balliet VP and Chief Culture Officer |
BUY
Grant, award, or other acquisition
|
Direct |
758
+2.71%
|
-
|
|
Jul 05
2021
|
Gina M Wallar President, Pharma Services |
BUY
Grant, award, or other acquisition
|
Direct |
1,896
+23.97%
|
-
|
|
Jul 05
2021
|
George Cardoza President & COO, Lab Ops |
BUY
Grant, award, or other acquisition
|
Direct |
7,584
+3.95%
|
-
|
|
Jun 22
2021
|
Cynthia J Dieter Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
56
-3.03%
|
$2,408
$43.99 P/Share
|
|
Jun 18
2021
|
Clive Morris President of Inivata |
BUY
Grant, award, or other acquisition
|
Direct |
10,708
+50.0%
|
-
|
|
Jun 11
2021
|
Lynn A. Tetrault Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,389
+3.82%
|
$12,501
$9.11 P/Share
|
|
Jun 08
2021
|
Bruce K Crowther Director |
SELL
Open market or private sale
|
Direct |
20,734
-29.49%
|
$850,094
$41.46 P/Share
|
|
Jun 08
2021
|
Bruce K Crowther Director |
BUY
Exercise of conversion of derivative security
|
Direct |
20,734
+7.41%
|
$352,478
$17.48 P/Share
|
|
Jun 03
2021
|
George Cardoza President & COO, Lab Ops |
SELL
Open market or private sale
|
Direct |
31,107
-14.96%
|
$1,244,280
$40.11 P/Share
|
|
Jun 02
2021
|
George Cardoza President & COO, Lab Ops |
SELL
Open market or private sale
|
Direct |
169,230
-44.88%
|
$6,769,200
$40.39 P/Share
|
|
Jun 02
2021
|
Stephen M Kanovsky Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,081
+25.09%
|
-
|
|
Jun 02
2021
|
Bruce K Crowther Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,081
+5.85%
|
-
|
|
Jun 02
2021
|
Lynn A. Tetrault Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,081
+8.41%
|
-
|
|
Jun 02
2021
|
Rachel A Stahler Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,081
+34.77%
|
-
|
|
Jun 02
2021
|
Kevin C Johnson Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,081
+8.29%
|
-
|
|
Jun 02
2021
|
Michael Aaron Kelly Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,081
+38.78%
|
-
|
|
Jun 02
2021
|
Alison L. Hannah Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,081
+3.24%
|
-
|
|
May 25
2021
|
Robert J. Shovlin President, Clinical Services |
SELL
Open market or private sale
|
Direct |
130,604
-46.53%
|
$5,093,556
$39.31 P/Share
|
|
May 25
2021
|
Robert J. Shovlin President, Clinical Services |
BUY
Exercise of conversion of derivative security
|
Direct |
126,958
+12.82%
|
$2,285,244
$18.65 P/Share
|
|
Apr 22
2021
|
Lawrence Martin Weiss Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
25,050
+6.4%
|
$475,950
$19.05 P/Share
|
|
Apr 19
2021
|
Mark Mallon Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
55,736
+50.0%
|
-
|
|
Mar 02
2021
|
Douglas Matthew Brown Chief Strategy Officer |
BUY
Grant, award, or other acquisition
|
Direct |
4,655
+4.0%
|
-
|
|
Mar 02
2021
|
Lawrence Martin Weiss Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,276
+4.75%
|
-
|
|
Mar 02
2021
|
George Cardoza President & COO, Lab Ops |
BUY
Grant, award, or other acquisition
|
Direct |
6,207
+1.62%
|
-
|
|
Mar 02
2021
|
Cynthia J Dieter Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,241
+40.2%
|
-
|
|
Mar 02
2021
|
Robert J. Shovlin President, Clinical Services |
BUY
Grant, award, or other acquisition
|
Direct |
6,827
+4.25%
|
-
|
|
Mar 02
2021
|
Robert J. Shovlin President, Clinical Services |
SELL
Payment of exercise price or tax liability
|
Direct |
608
-0.41%
|
-
|
|
Mar 02
2021
|
Denise E Pedulla General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
4,345
+6.69%
|
-
|
|
Mar 02
2021
|
Denise E Pedulla General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
216
-0.38%
|
-
|
|
Mar 02
2021
|
Jennifer Balliet VP and Chief Culture Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,862
+6.58%
|
-
|
|
Mar 02
2021
|
Jennifer Balliet VP and Chief Culture Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
173
-0.7%
|
-
|
|
Mar 02
2021
|
William Bonello Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
4,345
+21.92%
|
-
|
|
Mar 02
2021
|
William Bonello Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
432
-3.74%
|
-
|
|
Mar 02
2021
|
Douglas M Van Oort Director |
BUY
Grant, award, or other acquisition
|
Direct |
56,423
+2.23%
|
-
|
|
Mar 02
2021
|
Douglas M Van Oort Director |
SELL
Payment of exercise price or tax liability
|
Direct |
2,158
-0.09%
|
-
|
|
Mar 02
2021
|
Kathryn B Mc Kenzie Chief Sustainability/Risk Ofcr |
BUY
Grant, award, or other acquisition
|
Direct |
6,207
+31.44%
|
-
|
|
Mar 02
2021
|
Kathryn B Mc Kenzie Chief Sustainability/Risk Ofcr |
SELL
Payment of exercise price or tax liability
|
Direct |
432
-5.57%
|
-
|
|
Mar 01
2021
|
Robert J. Shovlin President, Clinical Services |
SELL
Payment of exercise price or tax liability
|
Direct |
742
-0.5%
|
-
|
|
Mar 01
2021
|
Denise E Pedulla General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
212
-0.37%
|
-
|
|
Mar 01
2021
|
Jennifer Balliet VP and Chief Culture Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
212
-0.85%
|
-
|
|
Mar 01
2021
|
William Bonello Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
500
-4.15%
|
-
|
|
Mar 01
2021
|
Douglas M Van Oort Director |
SELL
Payment of exercise price or tax liability
|
Direct |
2,339
-0.1%
|
-
|
|
Mar 01
2021
|
Kathryn B Mc Kenzie Chief Sustainability/Risk Ofcr |
SELL
Payment of exercise price or tax liability
|
Direct |
169
-2.13%
|
-
|
|
Jan 07
2021
|
Steven C Jones Director |
BUY
Exercise of conversion of derivative security
|
Direct |
17,286
+6.22%
|
$224,718
$13.8 P/Share
|
|
Jan 07
2021
|
Steven C Jones Director |
BUY
Exercise of conversion of derivative security
|
Indirect |
100,000
+8.33%
|
$700,000
$7.15 P/Share
|
|
Dec 14
2020
|
Lawrence Martin Weiss Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
20,200
-16.73%
|
$1,030,200
$51.06 P/Share
|
|
Dec 14
2020
|
Lawrence Martin Weiss Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
109,004
+19.33%
|
$1,199,044
$11.39 P/Share
|
|
Dec 14
2020
|
Steven C Jones Director |
SELL
Open market or private sale
|
Indirect |
25,000
-2.44%
|
$1,275,000
$51.67 P/Share
|
|
Dec 11
2020
|
Steven C Jones Director |
SELL
Open market or private sale
|
Indirect |
25,000
-2.38%
|
$1,250,000
$50.52 P/Share
|